Home
Diagnosis and Treatment
List of Medicines
Tisagenlecleucel Current Page

Tisagenlecleucel

Immunotherapy CAR T-Cell

Brand names:

Kymriah®

Often used for:

Acute lymphoblastic leukemia, Certain types of lymphoma

What is tisagenlecleucel?

Tisagenlecleucel (KYMRIAH) is a type of medicine called CAR T-Cell immunotherapy. This therapy works by engineering T cells to have special a receptor called a chimeric antigen receptor (CAR). This receptor helps T cells to recognize and attack cancer cells.

A serious condition called cytokine release syndrome (CRS) can occur after receiving this therapy. This usually occurs within the first 1-2 weeks of therapy. Patients will be monitored for CRS during the infusion and for at least 4 weeks after treatment. A medicine called tocilizumab may be given if CRS develops after receiving CART cell therapy.

Patients will have regular blood draws to check blood counts and immunoglobulin levels.

Given as a liquid into a vein by IV

Possible side effects

Cytokine release syndrome - symptoms can include:

Fever
Chills
Low blood pressure
Kidney problems
Liver problems
Shortness of breath
Low oxygen levels in the blood
Joint pain
Muscle pain

Neurologic effects - symptoms can include:

Headache
Seizures
Confusion
Tremors
Hallucinations
Altered mental status
Slurred speech
Dizziness

Low blood counts (may cause increased risk of infection, bleeding, anemia and/or fatigue)
Loss of appetite and weight loss
Nausea or vomiting
Constipation
Diarrhea
Fatigue or weakness
Skin rash
Abdominal pain
Back pain
Low potassium levels in the blood
Swelling of face or legs

Not all patients who take tisagenlecleucel will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.

Possible long-term or late effects

Some patients may experience long-term or late effects of treatment that may continue or develop months or years after treatment ends. Possible late effects due to tisagenlecleucel include:

Chronic infections
Second cancers

Tips for families

Be sure to discuss these and other recommendations with your doctor or pharmacist.

You will be given a Patient Wallet Card with information on the side effects of CAR T-cell therapy. Keep this card with you at all times.
You must stay within 2 hours of the hospital for at least 4 weeks after receiving the infusion unless otherwise indicated by your doctor.
Tisagenlecleucel may cause drowsiness, dizziness, confusion, and seizures. Patients should not drive or do anything that could be dangerous for at least 8 weeks after receiving the infusion.
In the case of severe cytokine release syndrome, patients may be treated with tocilizumab and/or corticosteroids.
Patients may be given diphenhydramine (Benadryl®), acetaminophen (Tylenol®), or other medicines to help prevent reactions during a tisagenlecleucel infusion.
Patients should not get certain types of vaccines (known as ‘live’ vaccines) for a period of time before or after receiving this medicine.
Sexually active patients should take steps to prevent pregnancy during treatment.
Patients should tell their doctor if they are pregnant or breastfeeding.

Learn More About Tisagenlecleucel

Print This Page

Always check the medication label. Many medicines look the same. Do not take any new medicine, including over-the counter medicines or supplements, without checking with your doctor or pharmacist. Talk to your doctor or pharmacist about what to do in the case of a missed dose, allergic reaction, or medical emergency.

This information is not intended to be a complete guide and is not a substitute for talking with your provider. Medicine names, appearance, formulas, or availability may vary by clinic location. Always follow the instructions given by your care team.